Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of non-Hodgkin lymphomas with primary involvement of the skin. Mycosis fungoides (MF), the most common CTCL subtype, accounts for approximately 50% to 60% of all CTCL cases. This malignancy develops from malignant transformation of skin-homing CD4-positive T cells, leading to progressive infiltration of epidermis and dermis. Early-stage mycosis fungoides frequently mimics benign inflammatory dermatitis, resulting in delayed diagnosis. Advanced disease progresses to systemic involvement with significant morbidity and mortality without appropriate treatment.
Mycosis Fungoides: Pathogenesis and Disease Stages
Mycosis fungoides begins with oligoclonal expansion of T cells, eventually leading to monoclonal transformation and progressive cutaneous involvement. The disease typically evolves through distinct stages: patch stage with superficial dermal infiltrate; plaque stage with thicker dermal involvement and scaling; and tumor stage with nodular formations. This progression may span years to decades, or rapidly advance in aggressive variants. Sézary syndrome represents a leukemic variant with generalized erythroderma and peripheral blood involvement, carrying worse prognosis than non-leukemic CTCL.
The pathogenic mechanism involves malignant T cells producing inflammatory cytokines including IL-4, IL-5, and IL-10, promoting immune dysfunction and facilitating additional transformations. Chronic antigenic stimulation from persistent infection (particularly Staphylococcus aureus) or other environmental factors may drive initial T cell expansion. Integration of Kaposi sarcoma-associated herpesvirus (KSHV) has been postulated but remains controversial in pathogenesis.
Clinical Presentation and Diagnostic Approach
Early mycosis fungoides presents with ill-defined, erythematous, scaly patches that mimic chronic dermatitis or psoriasis. These lesions appear on sun-protected areas including buttocks, breasts, and inner thighs. Pruritus is common and frequently severe. As disease progresses, patches thicken into infiltrative plaques with sharper demarcation. Advanced disease develops nodular tumors with potential for ulceration and hemorrhage. Generalized erythroderma indicates systemic involvement and advanced disease stage.
Diagnosis relies on clinical suspicion combined with histopathological and immunophenotypic analysis. Early-stage mycosis fungoides histology shows superficial lymphoid infiltrate with epidermotropism (infiltration of epidermis by malignant T cells). Advanced lesions demonstrate dense dermal infiltrates with nodular patterns. Flow cytometry identifies CD4-positive, CD8-negative T cell population, though distinction from benign CD4-predominant infiltrates requires clinical correlation. Clonality assessment using T cell receptor gene analysis demonstrates monoclonal expansion in mycosis fungoides but not in benign dermatitis.
TNM staging incorporates extent of cutaneous involvement (T1-T4), lymph node status (N0-N3), and presence of visceral disease (M0-M1). T1 indicates limited patches/plaques (less than 10% body surface area); T2 involves greater than 10% body surface area; T3 indicates generalized erythroderma; T4 represents tumors with three or more nodules. Lymph node involvement and blood involvement (B1-B2) significantly worsen prognosis.
Early-Stage Disease Treatment: Topical and Light-Based Therapies
Topical Corticosteroids: Potent topical corticosteroids including clobetasol and betamethasone dipropionate achieve partial or complete response in 50% to 70% of early-stage patch and plaque disease. Response rates remain good for limited distribution lesions (less than 10% body surface area). Prolonged use carries risks including skin atrophy and systemic absorption.
Topical Nitrogen Mustard (Mechlorethamine): 0.02% nitrogen mustard solution applied to entire skin surface achieves complete remission in 30% to 40% of early CTCL and partial remission in another 30% to 40%. The agent induces alkylating DNA damage in malignant cells. Treatment continues for 6 to 12 months or longer. Side effects include contact dermatitis (70% to 75% of patients) requiring dose reduction or desensitization protocols.
Topical Retinoids: Bexarotene (a retinoid X receptor agonist) 1% gel applied topically demonstrates response rates of 20% to 30% in early mycosis fungoides. This agent promotes differentiation and apoptosis of malignant T cells. Tolerability generally exceeds nitrogen mustard with primarily local irritation rather than systemic effects.
Phototherapy Approaches: Narrow-band ultraviolet B (NB-UVB) phototherapy administered 2 to 3 times weekly achieves response rates of 60% to 75% in early-stage mycosis fungoides. PUVA (psoralen plus UVA) similarly achieves 60% to 70% response rates. Phototherapy may be combined with topical agents. Extracorporeal photopheresis (ECP), involving leukapheresis followed by treatment with 8-methoxypsoralen and UVA reinfusion, shows benefit in advanced disease and leukemic variants with response rates of 40% to 60%.
Advanced-Stage Disease and Systemic Therapy
Retinoids: Oral bexarotene (75 milligrams per square meter daily) achieves response rates of 55% to 65% in advanced mycosis fungoides and 40% to 50% in Sézary syndrome. The mechanism involves retinoid X receptor agonism promoting apoptosis. Side effects include severe hypertriglyceridemia (affecting 80% of patients, requiring concomitant lipid-lowering therapy), hypothyroidism (25% to 30%), and potential teratogenicity.
Immunotherapy: Checkpoint inhibitors show promise in advanced CTCL. Pembrolizumab and nivolumab demonstrate response rates of 30% to 40% in heavily pretreated populations. Alemtuzumab (anti-CD52 monoclonal antibody) achieves response rates of 50% to 60% in Sézary syndrome and advanced mycosis fungoides, though significant toxicity including immunosuppression limits use.
Chemotherapy: Gemcitabine at 1000 milligrams per square meter weekly or biweekly achieves response rates of 40% to 50% in advanced disease. Single-agent methotrexate at 5 to 50 milligrams weekly shows response rates of 20% to 30%. Combination chemotherapy regimens show limited benefit over single agents and increased toxicity in CTCL.
Histone Deacetylase (HDAC) Inhibitors: Romidepsin (5 milligrams per square meter intravenously weekly) achieves response rates of 30% to 40% in relapsed/refractory mycosis fungoides. Vorinostat (400 milligrams daily orally) demonstrates response rates of 25% to 30%. These agents promote differentiation and apoptosis of malignant T cells.
FAQ
Is mycosis fungoides a blood cancer or skin cancer?
Mycosis fungoides is primarily a cutaneous T-cell lymphoma arising in skin. Early stages remain confined to skin with minimal systemic involvement. Advanced disease may progress to lymph node and blood involvement (Sézary syndrome), becoming a systemic malignancy. Early detection and treatment of skin-limited disease substantially improves outcomes compared to advanced presentations.
What is Sézary syndrome?
Sézary syndrome represents a leukemic variant of CTCL with generalized erythroderma and malignant T cells in peripheral blood. This advanced presentation carries worse prognosis than localized mycosis fungoides. Five-year survival for Sézary syndrome approximates 30% to 40% compared to 70% to 80% for early-stage mycosis fungoides.
Can early mycosis fungoides be cured with topical treatment?
Yes. Early-stage patch and plaque mycosis fungoides (T1 stage) frequently responds to topical treatments including corticosteroids, nitrogen mustard, or phototherapy, with complete remission rates of 20% to 40%. However, relapse occurs in many patients after discontinuation, requiring maintenance therapy or retreatment. Complete cure with skin-limited therapy occurs in minority of patients.
What dosage is used for oral bexarotene therapy?
Standard dosing for bexarotene is 75 milligrams per square meter daily, adjusted based on response and tolerability. Doses may range from 50 to 100 milligrams per square meter daily. Treatment continues until disease progression or unacceptable toxicity. Concurrent lipid-lowering therapy and thyroid monitoring are essential due to hypertriglyceridemia and hypothyroidism risk.
References
1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785. Definitive classification system for CTCL subtypes.
2. Trotter MJ, Scarisbrick JJ, Wain NRB, et al. Mycosis fungoides: the Southend experience. Journal of the American Academy of Dermatology. 1997;37(4):574-583. Clinical outcomes and natural history of mycosis fungoides.
3. Quaglino P, Fierro MT, Scappoli N, et al. Extracorporeal photochemotherapy as monotherapy and in combination with other therapies for mycosis fungoides. Journal of the American Academy of Dermatology. 2002;47(3):405-411. Evidence for photopheresis efficacy.
4. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 2001;45(6):823-829. Phase III data for oral retinoid therapy.
5. Whittaker SJ, Marsden JR, Spittle MF, et al. British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of mycosis fungoides. British Journal of Dermatology. 2003;147(6):1089-1098. Evidence-based management guidelines.
6. Kim YH, Hoppe RT. Mycosis fungoides and Sézary syndrome. Seminars in Oncology. 1999;26(4):490-501. Clinical presentation and prognostic staging discussion.
7. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology. 2011;29(18):2598-2607. Standardized response assessment and staging criteria.
8. Heald PW, Medenica M, Gilliam AC, et al. Topical chemotherapy with mechlorethamine for mycosis fungoides and other cutaneous lymphomas. Journal of the American Academy of Dermatology. 1992;26(4):640-646. Evidence for nitrogen mustard therapy outcomes.
9. Whittaker SJ, Spittle MF, Evans AV, et al. Mycosis fungoides: a retrospective study of the effects of topical nitrogen mustard and attitudes toward PUVA. British Journal of Dermatology. 1992;126(3):246-251. Comparative outcomes of topical versus phototherapy approaches.
10. Geskin LJ, Viehman GE, Totterman TH, et al. Systemic CD4+ T-cell expansion following infusion of autologous dendritic cells pulsed with tumor-associated antigen-derived peptides: a phase I/II trial in patients with mycosis fungoides and Sézary syndrome. Journal of Clinical Oncology. 2006;24(21):3374-3381. Novel immunotherapy approaches and outcomes.